BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol 2010; 2(3): 136-145 [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Paolicchi E, Pacetti P, Giovannetti E, Mambrini A, Orlandi M, Crea F, Romani AA, Tartarini R, Danesi R, Peters GJ, Cantore M. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncol Lett 2013;6:1487-91. [PMID: 24179546 DOI: 10.3892/ol.2013.1559] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, Alpini G, Alvaro D, Boberg KM, Locati M. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol. 2016;185:61-71. [PMID: 26864161 DOI: 10.1111/cei.12776] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
3 Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr 2012;54:580-7. [PMID: 22197937 DOI: 10.1097/MPG.0b013e31824711b7] [Cited by in Crossref: 77] [Cited by in F6Publishing: 19] [Article Influence: 8.6] [Reference Citation Analysis]
4 Segura-López FK, Avilés-Jiménez F, Güitrón-Cantú A, Valdéz-Salazar HA, León-Carballo S, Guerrero-Pérez L, Fox JG, Torres J. Infection with Helicobacter bilis but not Helicobacter hepaticus was Associated with Extrahepatic Cholangiocarcinoma. Helicobacter 2015;20:223-30. [PMID: 25582431 DOI: 10.1111/hel.12195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
5 Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Öllinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Höchst B, Wohlleber D, Jörs S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D, Heikenwalder M. Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. Cancer Cell 2017;31:771-789.e6. [PMID: 28609656 DOI: 10.1016/j.ccell.2017.05.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 16.8] [Reference Citation Analysis]
6 Rassam F, Roos E, van Lienden KP, van Hooft JE, Klümpen HJ, van Tienhoven G, Bennink RJ, Engelbrecht MR, Schoorlemmer A, Beuers UHW, Verheij J, Besselink MG, Busch OR, van Gulik TM. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. Langenbecks Arch Surg 2018;403:289-307. [PMID: 29350267 DOI: 10.1007/s00423-018-1649-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
7 Anderson JE, Hemming AW, Chang DC, Talamini MA, Mekeel KL. Surgical management trends for cholangiocarcinoma in the USA 1998-2009. J Gastrointest Surg 2012;16:2225-32. [PMID: 22847574 DOI: 10.1007/s11605-012-1980-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM, Bloomston M. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol 2014;21:133-8. [PMID: 24046106 DOI: 10.1245/s10434-013-3240-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
9 Tang B, Du J, Li Y, Tang F, Wang Z, He S. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3. Med Oncol 2014;31:271. [PMID: 25280519 DOI: 10.1007/s12032-014-0271-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
10 Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M, Orsini V, Jurisic G, Megel P, Makowska Z, Agarinis C, Tornillo L, Bouwmeester T, Ruffner H, Bauer A, Parker CN, Schmelzle T, Terracciano LM, Heim MH, Tchorz JS. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology 2015;62:1497-510. [PMID: 26173433 DOI: 10.1002/hep.27992] [Cited by in Crossref: 109] [Cited by in F6Publishing: 101] [Article Influence: 18.2] [Reference Citation Analysis]
11 Serafini FM, Radvinsky D. The pathways of genetic transformation in cholangiocarcinogenesis. Cancer Genet 2016;209:554-8. [PMID: 27720541 DOI: 10.1016/j.cancergen.2016.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Antunes CL, Antunes CL, Almeida TRO, Raposeiro N, Gonçalves B, Almeida P. Using a tubular electrode for radiofrequency ablation: Numerical and experimental analysis. COMPEL 2012;31:1077-86. [DOI: 10.1108/03321641211227320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Vasilieva LE, Papadhimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012;11:349-59. [PMID: 22893461 DOI: 10.1016/s1499-3872(12)60192-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
14 Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:301-8. [DOI: 10.1002/jhbp.62] [Cited by in Crossref: 119] [Cited by in F6Publishing: 95] [Article Influence: 17.0] [Reference Citation Analysis]
15 El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One. 2013;8:e77433. [PMID: 24204826 DOI: 10.1371/journal.pone.0077433] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
16 Payne SJ, Stebbing J, Wilson P, Slater S. Outcomes in unresectable and locally advanced resected cholangiocarcinoma. Expert Rev Anticancer Ther 2011;11:705-9. [PMID: 21554045 DOI: 10.1586/era.11.32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni M. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1:28. [PMID: 25332972 DOI: 10.3978/j.issn.2305-5839.2012.10.04] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
18 Barat S, Bozko P, Chen X, Scholta T, Hanert F, Götze J, Malek NP, Wilkens L, Plentz RR. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog 2016;55:2037-50. [PMID: 26757360 DOI: 10.1002/mc.22449] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
19 Kotawong K, Chaijaroenkul W, Muhamad P, Na-Bangchang K. Cytotoxic activities and effects of atractylodin and β-eudesmol on the cell cycle arrest and apoptosis on cholangiocarcinoma cell line. J Pharmacol Sci 2018;136:51-6. [PMID: 29525035 DOI: 10.1016/j.jphs.2017.09.033] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
20 Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552-1558. [PMID: 22503487 DOI: 10.1016/j.humpath.2011.12.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 128] [Article Influence: 15.2] [Reference Citation Analysis]
21 von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology 2011;46:1092-8. [DOI: 10.3109/00365521.2011.589472] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 7.2] [Reference Citation Analysis]
22 Müller SA, Mehrabi A, Rahbari NN, Warschkow R, Elbers H, Leowardi C, Fonouni H, Tarantino I, Schemmer P, Schmied BM, Büchler MW. Allogeneic Blood Transfusion Does Not Affect Outcome After Curative Resection for Advanced Cholangiocarcinoma. Ann Surg Oncol 2014;21:155-64. [DOI: 10.1245/s10434-013-3226-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
23 Boonjaraspinyo S, Wu Z, Boonmars T, Kaewkes S, Loilome W, Sithithaworn P, Nagano I, Takahashi Y, Yongvanit P, Bhudhisawasdi V. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int 2012;61:145-50. [PMID: 21777692 DOI: 10.1016/j.parint.2011.07.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
24 Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. Experimental and Molecular Pathology 2015;99:344-53. [DOI: 10.1016/j.yexmp.2015.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
25 Chen B, Zhou W, Zhao W, Yuan P, Tang C, Wang G, Leng J, Ma J, Wang X, Hui Y, Wang Q. Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling. Oncol Lett 2019;18:1989-98. [PMID: 31423269 DOI: 10.3892/ol.2019.10497] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Lin ZY, Liang ZX, Zhuang PL, Chen JW, Cao Y, Yan LX, Yun JP, Xie D, Cai MY. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels. BMC Cancer 2016;16:792. [PMID: 27733196 DOI: 10.1186/s12885-016-2827-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
27 Mansini AP, Peixoto E, Thelen KM, Gaspari C, Jin S, Gradilone SA. The cholangiocyte primary cilium in health and disease. Biochim Biophys Acta Mol Basis Dis 2018;1864:1245-53. [PMID: 28625917 DOI: 10.1016/j.bbadis.2017.06.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
28 Acharya B, Chaijaroenkul W, Na-Bangchang K. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways. J Pharm Pharmacol 2021:rgab036. [PMID: 33885818 DOI: 10.1093/jpp/rgab036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sandrasegaran K, Menias CO. Imaging and Screening of Cancer of the Gallbladder and Bile Ducts. Radiologic Clinics of North America 2017;55:1211-22. [DOI: 10.1016/j.rcl.2017.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
30 Macias RI. Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol 2014;2014:828074. [PMID: 27335842 DOI: 10.1155/2014/828074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
31 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
32 Abdel-Razik A, ElMahdy Y, Hanafy EE, Elhelaly R, Elzehery R, M Tawfik A, Eldars W. Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions. Am J Med Sci. 2016;351:259-264. [PMID: 26992254 DOI: 10.1016/j.amjms.2015.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
33 El Khatib M, Kalnytska A, Palagani V, Kossatz U, Manns MP, Malek NP, Wilkens L, Plentz RR. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 2013;57:1035-45. [DOI: 10.1002/hep.26147] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]